Design and synthesis of monocyclic beta-lactams as mechanism-based inhibitors of human cytomegalovirus protease. 1998

A D Borthwick, and G Weingarten, and T M Haley, and M Tomaszewski, and W Wang, and Z Hu, and J Bedard, and H Jin, and L Yuen, and T S Mansour
Department of Enzyme Medicinal Chemistry II, Glaxo Wellcome Research and Development, Medicines Research Centre, Stevenage, Herts, UK. adb3028@ggr.co.uk

Mechanism based inhibitors of HCMV protease have been designed based on the monocyclic beta-lactam nucleus, which have been shown to acylate the viral enzyme in a time dependent manner. SAR in a series of monocyclic beta-lactam N-ureas, has defined the size and relative stereochemistry of the C-3 substituent producing a low micromolar inhibitor 17b with good aqueous stability and selectivity over the mammalian serine proteases.

UI MeSH Term Description Entries
D007536 Isomerism The phenomenon whereby certain chemical compounds have structures that are different although the compounds possess the same elemental composition. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Isomerisms
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012697 Serine Endopeptidases Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis. Serine Endopeptidase,Endopeptidase, Serine,Endopeptidases, Serine
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D047090 beta-Lactams Four-membered cyclic AMIDES, best known for the PENICILLINS based on a bicyclo-thiazolidine, as well as the CEPHALOSPORINS based on a bicyclo-thiazine, and including monocyclic MONOBACTAMS. The BETA-LACTAMASES hydrolyze the beta lactam ring, accounting for BETA-LACTAM RESISTANCE of infective bacteria. beta-Lactam,4-Thia-1-Azabicyclo(3.2.0)Heptanes,4-Thia-1-Azabicyclo(4.2.0)Octanes,beta Lactam,beta Lactams

Related Publications

A D Borthwick, and G Weingarten, and T M Haley, and M Tomaszewski, and W Wang, and Z Hu, and J Bedard, and H Jin, and L Yuen, and T S Mansour
June 1998, Bioorganic & medicinal chemistry letters,
A D Borthwick, and G Weingarten, and T M Haley, and M Tomaszewski, and W Wang, and Z Hu, and J Bedard, and H Jin, and L Yuen, and T S Mansour
February 2002, Bioorganic & medicinal chemistry letters,
A D Borthwick, and G Weingarten, and T M Haley, and M Tomaszewski, and W Wang, and Z Hu, and J Bedard, and H Jin, and L Yuen, and T S Mansour
August 1993, Biochemistry,
A D Borthwick, and G Weingarten, and T M Haley, and M Tomaszewski, and W Wang, and Z Hu, and J Bedard, and H Jin, and L Yuen, and T S Mansour
April 2011, ACS chemical biology,
A D Borthwick, and G Weingarten, and T M Haley, and M Tomaszewski, and W Wang, and Z Hu, and J Bedard, and H Jin, and L Yuen, and T S Mansour
January 2004, Molecules (Basel, Switzerland),
A D Borthwick, and G Weingarten, and T M Haley, and M Tomaszewski, and W Wang, and Z Hu, and J Bedard, and H Jin, and L Yuen, and T S Mansour
July 1998, Journal of medicinal chemistry,
A D Borthwick, and G Weingarten, and T M Haley, and M Tomaszewski, and W Wang, and Z Hu, and J Bedard, and H Jin, and L Yuen, and T S Mansour
June 1975, Journal of medicinal chemistry,
A D Borthwick, and G Weingarten, and T M Haley, and M Tomaszewski, and W Wang, and Z Hu, and J Bedard, and H Jin, and L Yuen, and T S Mansour
January 2006, Molecules (Basel, Switzerland),
A D Borthwick, and G Weingarten, and T M Haley, and M Tomaszewski, and W Wang, and Z Hu, and J Bedard, and H Jin, and L Yuen, and T S Mansour
October 2000, Bioorganic & medicinal chemistry letters,
A D Borthwick, and G Weingarten, and T M Haley, and M Tomaszewski, and W Wang, and Z Hu, and J Bedard, and H Jin, and L Yuen, and T S Mansour
January 1984, Scandinavian journal of infectious diseases. Supplementum,
Copied contents to your clipboard!